DIA 48th Annual Meeting
Click here to go to the previous page
Noninferiority Trial Designs: Perspectives from Academia, Industry, and a Regulatory Agency
Track
:
Track 15: Statistical Science and Quantitative Thinking
Program Code:
258
Date:
Tuesday, June 26, 2012
Time:
1:30 PM to 3:00 PM
EST
CHAIR
:
Weishi Yuan, FDA, United States
PRESENTER
(S):
Brent Logan, Medical College of Wisconsin, United States
Kevin Carroll, Astrazeneca Pharmaceuticals LP, United Kingdom Rajeshwari Sridhara, FDA, United States
Description
There are more clinical trials done using noninferiority design in recent years. In this session, we have invited experts from these three fields to discuss their perspectives on noninferiority designs, method, and experiences.
Learning Objectives:
Define noninferiority (NI) trials
Interpret NI trial outcome
Identify issues involved in NI trial.
Learning Objectives:
Define noninferiority (NI) trials
Interpret NI trial outcome
Identify issues involved in NI trial.
This session is a part of:
Handout Online
